190965-42-5

Usage

Uses

Used in Pharmaceutical Research:
3-Propoxybenzoic acid is used as a building block for the preparation of various pharmaceutical derivatives and analogs, due to its unique chemical structure and properties. Its potential anti-inflammatory and analgesic properties make it a promising candidate for the development of new drugs.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Propoxybenzoic acid is used as a key intermediate for the synthesis of a wide range of organic compounds. Its reactivity and functional groups allow for various chemical reactions, enabling the creation of diverse molecules with different applications.
Used in Material Development:
3-Propoxybenzoic acid may have applications in the development of new materials, owing to its unique chemical structure and properties. It can potentially be incorporated into the design and synthesis of novel materials with specific characteristics, such as improved mechanical strength, thermal stability, or chemical resistance.
Used as a Precursor in Specialty Chemicals Production:
3-Propoxybenzoic acid can also serve as a precursor in the production of specialty chemicals, where its unique structure and properties can be utilized to create high-value chemical products. These specialty chemicals may find applications in various industries, such as coatings, adhesives, or fragrances, where specific performance characteristics are required.

Upstream product

• 7781-98-8 ethyl-3-hydroxybenzoate 
• 19438-10-9 methyl 3-hydroxybenzoate 
• 148433-10-7 methyl 3-propoxybenzoate 

Downstream Products

• 759393-68-5 3-propoxy-benzoic acid-(2-diethylamino-ethyl ester) 
• 1054632-48-2 C₆₂H₈₅NO₁₅Si₂ 
• 83230-74-4 3-propoxy-benzoyl chloride 

Relevant academic research and scientific papers

Demonstrating Ligandability of the LC3A and LC3B Adapter Interface

Autophagy is the common name for a number of lysosome-based degradation pathways of cytosolic cargos. The key components of autophagy are members of Atg8 family proteins involved in almost all steps of the process, from autophagosome formation to their selective fusion with lysosomes. In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin. Structure-activity relationship (SAR) studies of the 4-hydroxy coumarin core scaffold were performed, supported by a crystal structure of the LC3A dihydronovobiocin complex. The study reports the first nonpeptide inhibitors for these protein interaction targets and will lay the foundation for the development of more potent chemical probes for the Atg8 protein family which may also find applications for the development of autophagy-mediated degraders (AUTACs).

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist

Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist 6 was a suitable lead compound in terms of its high potent and low molecular size, while the docking study of compound 6 suggested a large unoccupied hydrophobic pocket, which might be provided more possibility of structure-activity relationship (SAR) study. In this study, we have performed comprehensive SAR and molecular modeling studies based on lead compound 6. All of these efforts resulted in the identification of a novel series of FXR partial agonists. In this series, compound 41 revealed the best activity and strong interaction with binding pocket of FXR. Moreover, compound 41 protected mice against acetaminophen-induced hepatotoxicity by the regulation of FXR-related gene expression and improving antioxidant capacity. In summary, these results suggest that compound 41 is a promising FXR partial agonist suitable for further investigation.

ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS

The present invention relates to pharmaceutical compounds for delivering active agents, such as biologically or chemically active agents, to a target. The invention also relates to pharmaceutical compositions comprising at least one delivery agent compound of the present invention and at least one active agent, and unit dosage forms comprising such compositions. Methods for the preparation and administration of the pharmaceutical compositions are also disclosed.